Resveratrol Supported on Magnesium DiHydroxide (Resv@MDH) Represents an Oral Formulation of Resveratrol With Better Gastric Absorption and Bioavailability Respect to Pure Resveratrol
Open Access
- 13 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 7
Abstract
Resveratrol attracts great interest because of the plethora of in vitro effects at the micromolar concentration range. Unfortunately, these effects are difficult to establish in vivo, due to the low concentration of resveratrol reached. This discrepancy is due to the molecules low solubility in water that favors the propensity for an intestinal absorption rather than in the gastric compartment. To address these challenges, we developed a Solid Dispersion of Resveratrol Supported by Magnesium Di Hydroxide formulation (Resv@MDH). This formulation displays increased water solubility and better bioavailability relative to pure resveratrol in the rabbit animal model. In our study, we evaluated the pharmacokinetics profile of resveratrol in six healthy human subjects following 180 mg of oral resveratrol administration, derived from Resv@MDH or pure resveratrol. Free resveratrol was evaluated in the whole blood sample by using HPLC - MS/MS. In comparison with pure resveratrol that displays an increase of the maximum plasma concentration, Cmax at about 90 min and 2 μM, Resv@MDH displays an earlier peak of resveratrol concentration with an increase of Cmax at about 30 min and 6 μM. The different kinetics suggest a main gastric route for resveratrol absorption from Resv@MDH, where, because of its improved dissolution rate, there seems to be a higher propensity for an acidic environment, as opposed to that with pure resveratrol. This conclusion is also supported by the numerical simulation analysis, which considers the principal steps during the oral route administration. Moreover, there is a 2-fold increase in the amount of free resveratrol with respect to pure resveratrol confirming a better bioavailability observed in the animal model. The characteristic feature of the pharmacokinetic profile of Resv@MDH implies that the beneficial properties of resveratrol in human health should be capitalized on it.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca
This publication has 27 references indexed in Scilit:
- Resveratrol and diabetes: from animal to human studiesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Resveratrol inhibits the acetylated α-tubulin-mediated assembly of the NLRP3-inflammasomeInternational Immunology, 2015
- Resveratrol Inhibits the Proliferation of Neural Progenitor Cells and Hippocampal NeurogenesisJournal of Biological Chemistry, 2012
- SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial FunctionCell Metabolism, 2012
- Administration of resveratrol: What formulation solutions to bioavailability limitations?Journal of Controlled Release, 2012
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Pharmacokinetic and safety profile oftrans‐resveratrol in a rising multiple‐dose study in healthy volunteersMolecular Nutrition & Food Research, 2009
- Quantification of free and protein‐bound trans‐resveratrol metabolites and identification of trans‐resveratrol‐C/O‐conjugated diglucuronides – Two novel resveratrol metabolites in human plasmaMolecular Nutrition & Food Research, 2008
- Stabilization and encapsulation of photosensitive resveratrol within yeast cellInternational Journal of Pharmaceutics, 2008
- Therapeutic potential of resveratrol: the in vivo evidenceNature Reviews Drug Discovery, 2006